Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Alafenamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Alafenamide SCHEMBL16402708 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL20456396 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL14440384 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL13155662 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL3107149 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL3107144 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL20456397 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL19467840 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL22139335 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL13964717 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017118928-A9 | PROCESS FOR THE SEPARATION OF DIASTEREOMERS OF TENOFOVIR ALAFENAMIDE | LUPIN LIMITED (IN) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017118928-A9 | PROCESS FOR THE SEPARATION OF DIASTEREOMERS OF TENOFOVIR ALAFENAMIDE | LUPIN LIMITED (IN) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017118928-A1 | PROCESS FOR THE SEPARATION OF DIASTEREOMERS OF TENOFOVIR ALAFENAMIDE | LUPIN LIMITED (IN) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017118928-A1 | PROCESS FOR THE SEPARATION OF DIASTEREOMERS OF TENOFOVIR ALAFENAMIDE | LUPIN LIMITED (IN) | 2017-07-13 | — | — | WO | disclosed |
| US-9676803-B2 | Efficient process for separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine | CIPLA LIMITED (IN) | 2017-06-13 | — | — | US | disclosed |
| US-9676803-B2 | Efficient process for separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine | CIPLA LIMITED (IN) | 2017-06-13 | — | — | US | disclosed |
| US-9676803-B2 | Efficient process for separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine | CIPLA LIMITED (IN) | 2017-06-13 | — | — | US | disclosed |
| US-20160122373-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL] METHOXY]PROPYL]ADENINE | CIPLA LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160122373-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL] METHOXY]PROPYL]ADENINE | CIPLA LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| EP-3004121-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL]METHOXY]PROPYL]ADENINE | Cipla Limited (IN) | 2016-04-13 | — | — | EP | disclosed |
| EP-3004121-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL]METHOXY]PROPYL]ADENINE | Cipla Limited (IN) | 2016-04-13 | — | — | EP | disclosed |
| EP-3004121-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL]METHOXY]PROPYL]ADENINE | Cipla Limited (IN) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195724-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL] METHOXY]PROPYL]ADENINE | CIPLA LIMITED (IN) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014195724-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL] METHOXY]PROPYL]ADENINE | CIPLA LIMITED (IN) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122373-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL] METHOXY]PROPYL]ADENINE | MTAP, PARP9, APRT | FAP 1817/4885CYP3A4 758/4885CYP2D6 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.